Zurabi Lominadze

Dr. Zurabi Lominadze

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2015 in Therapeutic Advances in Gastroenterology
Verified
Journal Article
Closed access
MRMary E. Rinella
Mary E. Rinella
ZLZurabi Lominadze
Zurabi Lominadze
RLRohit Loomba
Rohit Loomba
MCMichael Charlton
Michael Charlton
BNBrent A. Neuschwander-Tetri
Brent A. Neuschwander-Tetri
SHStephen A. Harrison
Stephen A. Harrison
Background: Management guidelines from the American Association for the Study of Liver Diseases/American College of Gastroenterology/American Gastroenterology Association published in 2012 for nonalcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) recommend weight loss, vitamin E and pioglitazone as effective therapies for the treatment of biopsy-confirmed NASH. However, little is known about how physicians in the US diagnose NASH or whether published guidelines are being followed. Methods: We assessed current diagnostic and treatment patterns of the management of NAFLD and NASH among academic gastroenterologists and hepatologists in the US using a standardized survey developed to collect information regarding respondents’ practice environments, diagnostic techniques, and medication usage in patients with NAFLD/NASH. Results: We invited 482 gastroenterologists and hepatologists, predominantly from academic centers, of whom 163 completed the survey. Only 24% of providers routinely perform liver biopsy, predominantly among patients with elevated serum aminotransferases. Vitamin E is prescribed regularly by 70% while only 14% routinely prescribe pioglitazone. Despite recommendations to the contrary, ~25% prescribe pioglitazone or vitamin E without biopsy confirmation of NASH. Metformin is used as frequently as pioglitazone despite its proven lack of efficacy in NASH. Overall, 40–73% adhere to published guidelines, depending on the specific question. There was no significant difference seen in adherence to guidelines between gastroenterologists and hepatologists. Conclusion: This survey suggests that clinical practice patterns among gastroenterologists and hepatologists for the management of NASH frequently diverge from published practice guidelines. Although liver biopsy remains the gold standard to diagnose NASH, less than 25% of respondents routinely require it to make the diagnosis of NASH. We conclude that NASH is underdiagnosed in gastroenterology and hepatology practices, highlighting the need to refine noninvasive diagnostic tools.

1 December 2012 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
RKRobert T Kavitt
Robert T Kavitt
THTina Higginbotham
Tina Higginbotham
JSJames C Slaughter
James C Slaughter
DPDilan Patel
Dilan Patel
EYElif Saritas Yuksel
Elif Saritas Yuksel
MVMichael F Vaezi
Michael F Vaezi
The American Journal of Gastroenterology is published by Nature Publishing Group (NPG) on behalf of the American College of Gastroenterology (ACG). Ranked the #1 clinical journal covering gastroenterology and hepatology*, The American Journal of Gastroenterology (AJG) provides practical and professional support for clinicians dealing with the gastroenterological disorders seen most often in patients. Published with practicing clinicians in mind, the journal aims to be easily accessible, organizing its content by topic, both online and in print. www.amjgastro.com, *2007 Journal Citation Report (Thomson Reuters, 2008)

1 October 2018 in Clinical Liver Disease
Verified
Journal Article
Open access
PDF file
ZLZurabi Lominadze
Zurabi Lominadze
EKEric R. Kallwitz
Eric R. Kallwitz
Watch a video presentation of this article

Verified
Journal Article
Open access
PDF file
ZLZurabi Lominadze
Zurabi Lominadze
KHKareen Hill
Kareen Hill
MSMohammed Rifat Shaik
Mohammed Rifat Shaik
JCJustin P. Canakis
Justin P. Canakis
MBMohammad Bourmaf
Mohammad Bourmaf
KSKirti Shetty
Kirti Shetty
The emerging field of immuno-oncology has brought exciting developments in the treatment of hepatocellular carcinoma (HCC). It has also raised urgent questions about the role of immunotherapy in the setting of liver transplantation, both before and after transplant. A growing body of evidence points to the safety and efficacy of immunotherapeutic agents as potential adjuncts for successful down-staging of advanced HCCs to allow successful transplant in carefully selected patients. For patients with recurrent HCC post-transplant, immunotherapy has a limited, yet growing role. In this review, we describe optimal regimens in the setting of liver transplantation.

1 April 2015 in ACG Case Reports Journal
Verified
Journal Article
Open access
ZLZurabi Lominadze
Zurabi Lominadze
LKLeila Kia
Leila Kia
SSSanjiv Shah
Sanjiv Shah
KPKeyur Parekh
Keyur Parekh
JLJosh Levitsky
Josh Levitsky
We report a 43-year-old man who presented for evaluation of ascites, varices, and hepatosplenomegaly. Initial labs were notable for normal platelets, mild liver synthetic dysfunction, and disproportionately elevated alkaline phosphatase. He was presumed to have underlying cirrhosis, and diuresis was attempted without success. A transjugular liver biopsy showed marked sinusoidal dilation without cirrhosis. Diagnostic paracentesis revealed fluid studies suggestive of cardiac ascites. Further cardiac evaluation confirmed constrictive pericarditis. The case highlights the importance of considering a broad differential in the evaluation of ascites.

1 September 2023 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
DLDavid U. Lee
David U. Lee
KSKimberly Schuster
Kimberly Schuster
ABAneesh Bahadur
Aneesh Bahadur
SSSophie Schellhammer
Sophie Schellhammer
RPReid Ponder
Reid Ponder
ZLZurabi Lominadze
Zurabi Lominadze